Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Contour Health vs REMEVi

Contour Health
Graded #177

Lower grade

vs+6.700000000000003
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 66.8/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueContour Health +8
65
57
Dose & formulationREMEVi +19
64
83
Clinical oversightREMEVi +1
85
86
Labs & monitoringREMEVi +2
53
55
FulfillmentREMEVi +27
70
97
Contract termsREMEVi +14
55
69
Contour Health · left barREMEVi · right bar

The numbers

MetricContour HealthREMEVi
WeighScore66.8/10073.5/100
GradeCC
Scorecard rank#177#70
Semaglutide$160/mo (starting dose, compounded)$219/mo
Tirzepatide$300/mo (starting dose, compounded)$319/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Contour Health

Graded #177 · C

Strengths

  • Free medical consultation — no charge to talk with a provider before starting
  • Pay-per-vial pricing with no long-term subscription commitment required to participate
  • Names its compounding pharmacy partner (Strive Pharmacy, 503A accredited) — a real transparency signal
  • LegitScript badge links to a genuine, working LegitScript verification checker for the domain
  • Board-certified Medical Director and named nurse-practitioner care team, not anonymous providers

Where it loses points

  • State availability list is not published — Terms of Service only says "certain states"
  • All product purchases are non-refundable per Terms of Service
  • Compounded injectable only — no oral option, no brand-name Wegovy/Zepbound/Ozempic/Mounjaro
  • Terms of Service also describe an optional subscription tier with a 3-month minimum, despite marketing emphasizing "no subscriptions"
  • No insurance, Medicare, or Medicaid accepted — cash-pay or HSA/FSA only
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard